PolyPid Ltd at Raymond James Human Health Innovation Conference (Virtual) Transcript
Good morning. Welcome to the PolyPid presentation at Raymond James Annual Health and Human Innovation Conference. I'm Elliot Wilbur, the specialty pharmaceutical analyst at Raymond James and the coverage analyst on PolyPid.
For those of you not familiar with the story, PolyPid is a clinical-stage biopharma company that's focused on developing and commercializing locally administered therapies to improve surgical outcomes, utilizing the Company's proprietary PLEX drug matrix technology.
Providing us with an overview of the Company and an update on many recent developments is Dikla Czaczkes Akselbrad, the Company's Chief Financial Officer. Dikla?
Thank you, Elliot, and good morning, everyone. And thank you for the opportunity to share with you some of the recent developments that happened in PolyPid, both in regulatory and clinically.
So as Elliot presented us very nicely, we are a late-stage, Phase 3 now
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
